Surgery Partners, Inc. (SGRY) Form 8-K — Nov 9, 2026
Surgery Partners reported Q3 2026 revenue of $815.3 million, down 0.8% YoY, with a net loss attributable to the company of $21.1 million and Adjusted EBITDA of $132.7 million versus $136.4 million a year ago. Same-facility revenues grew 6.0%, masking consolidated softness tied to the Idaho Falls divestiture. The company also amended its merger agreement with HealthSpan Partners, raising the cash consideration to $25.00 per share (enterprise value up to ~$6.0 billion) after receiving an unsolicited competing proposal. A new Ticking Fee pays non-Bain stockholders 10% per annum monthly if the deal slips past March 1, 2027.
Key figures
- Revenue
- 815300000
- Revenue Yoy
- -0.8%
- Cash Position
- 354500000
- Enterprise value
- ~$6.0 billion
- Ticking fee rate
- 10% per annum on $25.00 per share if merger not closed by March 1, 2027
- Revolver capacity
- $692.8M
- Adjusted ebitda q3
- $132.7M vs $136.4M prior year
- Net debt to ebitda
- 4.4x
- Adjusted ebitda ytd
- $360.2M vs $369.3M prior year
- Merger price per share
- $25.00
- Operating cash flow q3
- $103.5M vs $83.6M prior year
- Same facility revenue growth q3
- 6.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.